Clinical Evidence for Hemodynamic Optimization through Perioperative Goal-Directed Therapy

When applied intraoperatively, hemodynamic optimization through PGDT has been shown to reduce post-surgical complications, hospital length of stay and associated costs across a wide range of moderate to high-risk surgical populations.

Reduction in Post-Surgical Morbidity


Advanced Hemodynamic Parameters when used in Perioperative Goal-Directed Therapy are Key to Optimize Volume Administration

Advance hemodynamic parameters – such as stroke volume, SV; stroke volume variation, SVV; and cardiac output, CO – when combined with a PGDT protocol, can more effectively guide volume administration than conventional care. Edwards provides a range of monitoring options, including the ClearSight and FloTrac systems, that can be used in PGDT protocols to hemodynamically optimize patients.

FloTrac Minimally-Invasive System

**PGDT outcome**


ccNexfin/ClearSight Noninvasive System†

**PGDT outcome**


† All studies listed were conducted using the ccNexfin system. The ccNexfin system technology – including the algorithm, Physioscal, volume clamp method, and brachial BP reconstruction for BP – are also included in the ClearSight system.
FloTrac Minimally-Invasive System

PGDT outcome (continued)


Application*


Validation**

Cardiac Output / Stroke Volume Variation


Stroke Volume Variation


Cardiac Output


ccNexfin / ClearSight Noninvasive System†

Application*


Validation**

Cardiac Output


Blood Pressure


References


All information provided by Edwards Lifesciences is gathered from third party sources and is presented for informational purposes only. This information is not intended to describe, recommend, or suggest any use, feature, or benefit of any Edwards product and does not constitute reimbursement, medical or legal advice. Edwards makes no representation or warranty regarding this information or its completeness, accuracy or timeliness. It is not intended to make a recommendation regarding clinical practice and service providers are responsible for all decisions relating to clinical services.

For professional use. CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, ccNexfin, ClearSight, FloTrac, Nefxin, and Vigileo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2014 Edwards Lifesciences Corporation. All rights reserved. AR11583